 |
| |
| |
| |
| |
| |
| |
|
| TissGeneSummary for HPR |
 Gene summary |
| Basic gene information | Gene symbol | HPR |
| Gene name | haptoglobin-related protein | |
| Synonyms | A-259H10.2|HP | |
| Cytomap | UCSC genome browser: 16q22.1 | |
| Type of gene | protein-coding | |
| RefGenes | NM_020995.3, | |
| Description | Haptoglobin-related locus | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 140210 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000261701 | ||
| HPRD : 00773 | ||
| Vega : OTTHUMG00000173010 | ||
| Protein | UniProt: go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_HPR | |
| BioGPS: 3250 | ||
| Pathway | NCI Pathway Interaction Database: HPR | |
| KEGG: HPR | ||
| REACTOME: HPR | ||
| Pathway Commons: HPR | ||
| Context | iHOP: HPR | |
| ligand binding site mutation search in PubMed: HPR | ||
| UCL Cancer Institute: HPR | ||
| Assigned class in TissGDB* | A | |
| Included tissue-specific gene expression resources | HPA,TiGER,GTEx | |
| Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Liver | |
| Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | LIHC | |
| Reference showing the relevant tissue of HPR | An intronic endogenous retrovirus-like sequence attenuates human haptoglobin-related gene expression in an orientation-dependent manner. Hatada S, Grant DJ, Maeda N. Gene. 2003 Nov 13;319:55-63. (pmid:14597171) go to article | |
| Description by TissGene annotations | Cancer gene | |
| * Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO term | PubMed ID |
| Top |
| TissGeneExp for HPR |
| Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
 |
| Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
 |
| Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| - Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
| Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
| PRAD | -1.007728373 | 0.006131243 | -1.013859615 | 1.54E-05 | 8.04E-05 |
| LUAD | 0.457058033 | 1.993151137 | -1.536093103 | 1.64E-07 | 6.20E-07 |
| BRCA | -1.24550452 | -0.209413292 | -1.036091228 | 5.69E-16 | 3.16E-15 |
| LUSC | -0.220321548 | 2.368109825 | -2.588431373 | 5.23E-14 | 2.80E-13 |
| LIHC | 10.71061555 | 12.57351955 | -1.862904 | 7.18E-05 | 0.000255913 |
| Top |
| TissGene-miRNA for HPR |
| Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
| Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
| Top |
| TissGeneMut for HPR |
| TissGeneSNV for HPR |
| nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
 |
 |
| Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
 |
| - nsSNVs sorted by frequency. |
| AAchange | Cancer type | # samples |
| p.E278K | SKCM | 2 |
| p.S22* | BLCA | 2 |
| p.D333N | CESC | 1 |
| p.G5R | SKCM | 1 |
| p.Q53K | CESC | 1 |
| p.G113S | SKCM | 1 |
| p.S286P | HNSC | 1 |
| p.S224F | PAAD | 1 |
| p.V260M | CESC | 1 |
| p.E176Q | COAD | 1 |
| p.Q118H | COAD | 1 |
| p.G221S | LUAD | 1 |
| p.N213D | STAD | 1 |
| p.G5E | SKCM | 1 |
| p.G92R | SKCM | 1 |
| p.Q273X | THYM | 1 |
| p.A119V | PAAD | 1 |
| p.D236E | LUAD | 1 |
| p.R33C | COAD | 1 |
| p.N277H | UCEC | 1 |
| p.L48F | BLCA | 1 |
| p.A154E | LUAD | 1 |
| p.H339D | KIRP | 1 |
| p.H339D | STAD | 1 |
| p.R60H | COAD | 1 |
| p.W13* | SKCM | 1 |
| p.G14R | SKCM | 1 |
| p.G295D | SKCM | 1 |
| p.I207M | ESCA | 1 |
| p.K343N | HNSC | 1 |
| p.D28N | SKCM | 1 |
| p.Q16K | CESC | 1 |
| p.A131S | SARC | 1 |
| p.I134N | LUAD | 1 |
| p.D305N | SKCM | 1 |
| p.S268I | SARC | 1 |
| p.G63R | SKCM | 1 |
| p.Y56N | STAD | 1 |
| p.S211* | UCEC | 1 |
| p.H339R | TGCT | 1 |
| p.A313T | UCEC | 1 |
| p.E256K | BLCA | 1 |
| p.G190E | HNSC | 1 |
| p.F49S | PRAD | 1 |
| p.P269A | LUAD | 1 |
| p.Y67* | UCEC | 1 |
| p.R33H | HNSC | 1 |
| p.A313V | STAD | 1 |
| p.R58K | LUSC | 1 |
| p.T253M | STAD | 1 |
| p.T344S | LUAD | 1 |
| p.D320G | KICH | 1 |
| p.D296N | COAD | 1 |
| p.V200F | LUAD | 1 |
| Top |
| TissGeneCNV for HPR |
| Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
 |
| Top |
| TissGeneFusions for HPR |
| Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
| Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
| Top |
| TissGeneNet for HPR |
| Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
| BRCA (tumor) | BRCA (normal) |
| HPR, APOA1, CD40LG (tumor) | HPR, APOA1, CD40LG (normal) |
 |  |
| COAD (tumor) | COAD (normal) |
| HPR, APOA1, CD40LG (tumor) | HPR, APOA1, CD40LG (normal) |
 |  |
| HNSC (tumor) | HNSC (normal) |
| HPR, APOA1, CD40LG (tumor) | HPR, APOA1, CD40LG (normal) |
 |  |
| KICH (tumor) | KICH (normal) |
| HPR, APOA1, CD40LG (tumor) | HPR, APOA1, CD40LG (normal) |
 |  |
| KIRC (tumor) | KIRC (normal) |
| HPR, APOA1, CD40LG (tumor) | HPR, APOA1, CD40LG (normal) |
 |  |
| KIRP (tumor) | KIRP (normal) |
| HPR, APOA1, CD40LG (tumor) | HPR, APOA1, CD40LG (normal) |
 |  |
| LIHC (tumor) | LIHC (normal) |
| HPR, APOA1, CD40LG (tumor) | HPR, APOA1, CD40LG (normal) |
 |  |
| LUAD (tumor) | LUAD (normal) |
| HPR, APOA1, CD40LG (tumor) | HPR, APOA1, CD40LG (normal) |
 |  |
| LUSC (tumor) | LUSC (normal) |
| HPR, APOA1, CD40LG (tumor) | HPR, APOA1, CD40LG (normal) |
 |  |
| PRAD (tumor) | PRAD (normal) |
| HPR, APOA1, CD40LG (tumor) | HPR, APOA1, CD40LG (normal) |
 |  |
| STAD (tumor) | STAD (normal) |
| HPR, APOA1, CD40LG (tumor) | HPR, APOA1, CD40LG (normal) |
 |  |
| THCA (tumor) | THCA (normal) |
| HPR, APOA1, CD40LG (tumor) | HPR, APOA1, CD40LG (normal) |
 |  |
| Top |
| TissGeneProg for HPR |
| Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
 |
| Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Top |
| TissGeneClin for HPR |
| TissGeneDrug for HPR |
| Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
| DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Top |
| TissGeneDisease for HPR |
| Disease information associated with TissGene (DisGeNet, 2016-06-01) |
| Disease ID | Disease name | # pubmeds | Source |
| umls:C0027819 | Neuroblastoma | 7 | BeFree |
| umls:C0678222 | Breast Carcinoma | 6 | BeFree |
| umls:C0006142 | Malignant neoplasm of breast | 5 | BeFree |
| umls:C0700095 | Central neuroblastoma | 5 | BeFree |
| umls:C0029925 | Ovarian Carcinoma | 4 | BeFree |
| umls:C0376358 | Malignant neoplasm of prostate | 4 | BeFree |
| umls:C0600139 | Prostate carcinoma | 4 | BeFree |
| umls:C1140680 | Malignant neoplasm of ovary | 3 | BeFree |
| umls:C0005684 | Malignant neoplasm of urinary bladder | 2 | BeFree |
| umls:C0017636 | Glioblastoma | 2 | BeFree |
| umls:C0023418 | leukemia | 2 | BeFree |
| umls:C0027627 | Neoplasm Metastasis | 2 | BeFree |
| umls:C0032927 | Precancerous Conditions | 2 | BeFree |
| umls:C0677886 | Epithelial ovarian cancer | 2 | BeFree |
| umls:C0699885 | Carcinoma of bladder | 2 | BeFree |
| umls:C0007103 | Malignant neoplasm of endometrium | 1 | BeFree |
| umls:C0017638 | Glioma | 1 | BeFree |
| umls:C0023449 | Acute lymphocytic leukemia | 1 | BeFree |
| umls:C0023467 | Leukemia, Myelocytic, Acute | 1 | BeFree |
| umls:C0023903 | Liver neoplasms | 1 | BeFree |
| umls:C0024530 | Malaria | 1 | BeFree |
| umls:C0041227 | Trypanosomiasis | 1 | BeFree |
| umls:C0041228 | African Trypanosomiasis | 1 | BeFree |
| umls:C0149925 | Small cell carcinoma of lung | 1 | BeFree |
| umls:C0451641 | Urolithiasis | 1 | BeFree |
| umls:C0476089 | Endometrial Carcinoma | 1 | BeFree |
| umls:C0596263 | Carcinogenesis | 1 | BeFree |
| umls:C0877008 | Enzyme inhibition disorder | 1 | BeFree |
| umls:C1291317 | Deficiency of transferase | 1 | BeFree |
| umls:C1458155 | Mammary Neoplasms | 1 | BeFree |
| umls:C1883486 | Uterine Corpus Cancer | 1 | BeFree |
| umls:C1961102 | Precursor Cell Lymphoblastic Leukemia Lymphoma | 1 | BeFree |
| umls:C2239176 | Liver carcinoma | 1 | BeFree |
| umls:C3279786 | ANHAPTOGLOBINEMIA | 1 | BeFree |
Copyright 2016-Present - The University of Texas Health Science Center at Houston (UTHealth) Web File Viewing | How to Report, Fraud, Waste and Abuse | State of Texas | Statewide Search | Texas Homeland Security | Site Policies |